Stem Cell and Regenerative Medicine in Massachusetts: What’s Legal and What to Know

Last reviewed: 5/2026 · Verify current state guidance before relying on any specific claim

Massachusetts has one of the most developed state-level regulatory frameworks for stem cell research in the country, anchored by Chapter 27 of the Acts of 2005 — the Act Enhancing Regenerative Medicine in the Commonwealth — and its implementing regulations at 105 CMR 960.000. Institutions conducting human embryonic stem cell research in the Commonwealth must obtain a Certificate of Registration from the Department of Public Health. The state is the country’s densest biotech corridor, with Harvard, MIT, the Whitehead Institute, Mass General Brigham, and the Dana-Farber Cancer Institute operating active regenerative medicine research programs in Boston and Cambridge. Massachusetts adopted a Right to Try law in 2017. The Massachusetts Board of Registration in Medicine regulates physicians; there is no Massachusetts-specific commercial stem cell statute beyond the research-oriented framework.

For the federal framework that applies in every state — FDA regulation of cell and tissue products under 21 CFR Part 1271, the 361/351 distinction, FDA enforcement history, and the federal Right to Try Act — see How Regenerative Medicine Is Regulated in the United States.

Massachusetts’s Biotechnology Statute and Stem Cell Regulations

The Biotechnology Statute, M.G.L. Chapter 111L, enacted by Chapter 27 of the Acts of 2005, established Massachusetts as a state actively supporting regenerative medicine research while imposing structured oversight. Implementing regulations are codified at 105 CMR 960.000 (Biotechnology — stem cell research).

Key elements of the framework:

  • Any institution conducting human embryonic stem cell research in Massachusetts must obtain a Certificate of Registration from the Massachusetts Department of Public Health.
  • The statute and regulations govern the source, handling, and research use of embryonic stem cells; they do not directly govern commercial clinical stem cell therapy.
  • The framework is permissive of legitimate research while imposing transparency and ethical-oversight requirements.

Official state resource: Massachusetts law about stem cell research (Mass.gov). Additional background: Human Embryonic Stem Cell Research (Mass.gov).

The Massachusetts Board of Registration in Medicine

The Massachusetts Board of Registration in Medicine licenses and disciplines allopathic physicians and acupuncturists in the Commonwealth. The Board operates under M.G.L. Chapter 112 and 243 CMR.

As of late 2025 [VERIFY current Board publications], the Board has not issued comprehensive guidance specific to commercial stem cell, PRP, NAD+, or peptide therapy. Standard practice-of-medicine rules apply, and the Board’s complaint and licensure verification tools are accessible through Mass.gov.

The Federation of State Medical Boards’ periodic board-by-board overview of regenerative and stem cell therapy regulation tracks state-level guidance as it evolves and is a useful cross-reference.

Massachusetts’s Right to Try Law

Massachusetts enacted Right to Try legislation in 2017 [VERIFY exact act number and session]. The Massachusetts law operates in parallel with the federal Right to Try Act of 2018 and allows eligible patients with terminal illnesses to access investigational drugs, biological products, and devices that have completed FDA Phase 1 clinical trials.

The Massachusetts statute does not authorize clinics to offer unapproved stem cell, exosome, or peptide therapies outside the narrow conditions of the Act — terminal diagnosis, exhausted FDA-approved options, physician recommendation, access through the actual sponsor of an investigational product.

Massachusetts’s Regenerative Medicine Research Infrastructure

The Boston/Cambridge corridor is the largest concentration of regenerative medicine research in the country. Active institutions include:

  • Harvard Stem Cell Institute — pan-Harvard regenerative medicine consortium spanning Harvard Medical School, Harvard School of Public Health, the Faculty of Arts and Sciences, and affiliated hospitals.
  • Massachusetts Institute of Technology — Koch Institute and broader biology departments run active stem cell and tissue-engineering programs.
  • Whitehead Institute for Biomedical Research — independent affiliate of MIT.
  • Mass General Brigham (formerly Partners HealthCare) — clinical translational programs at Massachusetts General Hospital and Brigham and Women’s Hospital.
  • Dana-Farber Cancer Institute — hematologic stem cell transplant and cell therapy programs.
  • Boston Children’s Hospital — pediatric cell therapy and gene therapy programs.

Patients in Massachusetts with an interest in legitimate experimental access should search clinicaltrials.gov for active trials at these institutions before considering cash-pay options at commercial clinics.

IV Therapy and NAD+ in Massachusetts

NAD+ intravenous therapy is broadly available in Massachusetts. Registered nurses may administer IV under physician orders, and nurse practitioners have full practice authority in Massachusetts (granted via 2020 legislation), allowing them to prescribe and supervise IV therapy independently. IV lounges, mobile IV services, and concierge IV providers operate in Boston, Cambridge, Worcester, Springfield, and other metros.

NAD+ itself is compounded through 503A or 503B pharmacies and is not FDA-approved for any indication. Patients pay out of pocket.

Telemedicine and Out-of-State Providers

Massachusetts is not currently a member of the Interstate Medical Licensure Compact [VERIFY current status]. Out-of-state physicians must obtain Massachusetts licensure through the standard licensure process. Massachusetts does permit telehealth practice by Massachusetts-licensed physicians, subject to standard-of-care requirements.

Notable Enforcement

The FDA’s public Warning Letter database is the authoritative source for enforcement against specific Massachusetts-based clinics [VERIFY against current list]. The 2021 federal injunction in United States v. US Stem Cell Clinic, LLC applies in Massachusetts as in every state.

Massachusetts has not been a notable focus of state attorney general action against the commercial regenerative medicine sector, in part because the dense research infrastructure has historically channeled cell therapy work through academic medical centers rather than standalone commercial clinics.

Cost and Clinic Landscape

Regenerative medicine clinics in Massachusetts cluster in Boston, Cambridge, Worcester, Springfield, and the South Shore. Celmedica currently lists [X] verified clinics across Massachusetts — pull live count.

Typical out-of-pocket pricing in Massachusetts (representative ranges; individual clinics vary):

  • PRP joint injection: $600 – $1,800 per session (Boston pricing trends higher)
  • Autologous stem cell injection (single joint or area): $5,500 – $11,000
  • NAD+ IV (single drip): $500 – $1,000
  • Peptide protocols: $250 – $1,400 per month, varies by compound

Insurance generally does not cover regenerative therapies. Some orthopedic indications for PRP are occasionally covered.

The exceptional density of academic medical centers in Massachusetts means that clinical-trial access for legitimate investigational protocols — sometimes at no cost — is often realistic and worth investigating before pursuing cash-pay options.

Frequently Asked Questions

Is stem cell therapy legal in Massachusetts? Massachusetts has a structured statutory and regulatory framework for embryonic stem cell research (M.G.L. c.111L, 105 CMR 960.000). Commercial adult/autologous stem cell therapy is not specifically governed by Massachusetts statute; it operates under federal FDA rules and Massachusetts Board of Registration in Medicine practice standards.

Does Massachusetts require institutional registration for stem cell research? Yes. Institutions conducting human embryonic stem cell research in Massachusetts must obtain a Certificate of Registration from the Massachusetts Department of Public Health under 105 CMR 960.000.

How does Massachusetts’s Right to Try law apply to stem cell therapy? Only in the narrow case of investigational stem cell products that have completed FDA Phase 1 trials, for a patient with a terminal illness, accessed through the actual product sponsor. It does not authorize clinics to offer unapproved stem cell therapy as a routine cash-pay service.

How much does stem cell therapy cost in Boston? Autologous stem cell injections for a single joint typically range $5,500–$11,000 in Boston-area clinics — higher than national averages. PRP runs $600–$1,800. Clinical-trial participation at Harvard-affiliated hospitals, MGH, BWH, or Dana-Farber is sometimes available and meaningfully cheaper or free.

Can nurse practitioners administer NAD+ IV therapy in Massachusetts? Yes. Massachusetts granted nurse practitioners full practice authority in 2020, including independent prescribing. NPs may prescribe and supervise NAD+ IV therapy within their scope of practice.

Bottom Line

Massachusetts has one of the most developed research-oriented stem cell regulatory frameworks of any U.S. state, combined with the country’s deepest concentration of academic regenerative medicine programs. For commercial stem cell therapy, the federal framework dominates; Massachusetts adds its own Right to Try statute and Board of Registration practice rules. Patients should focus on physician credentials, FDA product classification of the specific therapy, and whether clinical-trial access is available at one of the major Boston-area academic medical centers before considering cash-pay options.

Next steps:

[FTC affiliate disclosure block]: Some links in this guide may earn Celmedica a commission at no additional cost to you. Read our affiliate disclosure.

[Medical disclaimer]: This guide is for informational purposes and does not constitute legal or medical advice. State laws and regulatory guidance change. Verify current rules with the Massachusetts Board of Registration in Medicine, the Department of Public Health, and the FDA, and consult a qualified physician before pursuing any therapy.

References

For the federal regulatory citations, see the federal baseline references.

Massachusetts-specific: